Title: Cutaneous *Leishmania mexicana* Infections in the United States: Defining Strains Through Endemic Human Pediatric Cases in Northern Texas

Authors: Binita Nepal, Ph.D.[1, 2]; Clare McCormick-Baw, M.D., Ph.D.[3]; Karisma Patel, Pharm. D.[1]; Sarah Firmani, Pharm. D.[1]; Dawn M. Wetzel, M.D., Ph.D.[1, 2, *]

Affiliations: Departments of [1]Pediatrics, [2]Biochemistry, and [3]Pathology, University of Texas Southwestern Medical Center

*Corresponding author: Dawn M. Wetzel, M.D., Ph.D., Department of Pediatrics and Biochemistry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390; phone 214-645-9510; fax 214-648-2961; email: dawn.wetzel@utsouthwestern.edu

Running title: Endemic leishmaniasis in the United States

Keywords: cutaneous, *Leishmania mexicana*, leishmaniasis, pediatrics, parasitology, Texas

Abbreviations: 6 phosphogluconate dehydrogenase (6PGD), Centers for Disease Control and Prevention (CDC), Infectious Diseases (ID), Infectious Disease Society of America (IDSA), malate dehydrogenase (MDH), mannose phosphate isomerase (MPI), multi-locus sequence analysis (MLSA), polymerase chain reaction (PCR), University of Texas Southwestern Medical Center (UTSW), United States (US)

Word counts: Manuscript 1940/2000; Abstract 248/250; Importance 144/150

ABSTRACT

Over a six-month span, three patients under five years old with cutaneous leishmaniasis presented to the Pediatric Infectious Diseases Clinic at the University of Texas Southwestern Medical Center/Children's Health Dallas. None had traveled outside of the United States (US); all had confirmed *L. mexicana* infections by PCR. We provide case descriptions and images to increase the awareness of this disease among US physicians and scientists. Two patients responded to fluconazole, but one required topical paromomycin. Combining these cases with guidelines and our literature review, we suggest that: 1) higher doses (ten-twelve mg/kg/day) of fluconazole should be considered in young children to maximize likelihood and rapidity of response and 2) patients should transition to alternate agents if they do not respond to high-dose fluconazole within six weeks. Furthermore, and of particular interest to the broad microbiology community, we used samples from these cases as a proof-of-concept to propose a mechanism to strain-type US-endemic *L. mexicana.* For our analysis, we sequenced three housekeeping genes and the internal transcribed sequence 2 of the ribosomal RNA gene. We identified genetic changes that not only allow us to distinguish US-based *L. mexicana* strains from strains found in other areas of the Americas, but also establish polymorphisms that differ between US isolates. These techniques will allow documentation of genetic changes in this parasite as its range expands. Hence, our cases of cutaneous leishmaniasis provide significant evolutionary, treatment and public health implications as climate change increases exposure to formerly tropical diseases in previously non-endemic areas.

IMPORTANCE

Leishmaniasis is a parasitic disease that typically affects tropical regions worldwide. However, the vector that carries *Leishmania* is spreading northward into the United States (US). Within a six-month period, three young cutaneous leishmaniasis patients were seen at the Pediatric Infectious Diseases Clinic at The University of Texas Southwestern/Children's Health Dallas. None had traveled outside of north Texas. We document their presentations, treatments, and outcomes and compare their management to clinical practice guidelines for leishmaniasis. We also analyzed the sequences of three critical genes in *Leishmania mexicana* isolated from these patients. We found changes that not only distinguish US-based strains from strains found elsewhere, but also differ between US isolates. Monitoring these sequences will allow tracking of genetic changes in parasites over time. Our findings have significant US public health implications as people are increasingly likely to be exposed to what were once tropical diseases.

INTRODUCTION

Leishmaniasis is caused by obligate intracellular parasites of the genus *Leishmania*, which are spread by *Lutzomyia* and *Phlebotomus* sand flies. A spectrum of human illness results, including cutaneous, mucocutaneous, and visceral disease. Disease manifestations are governed by the infecting parasite species and host immune status *(1)*.

Generations of medical providers and infectious diseases specialists have been taught that leishmaniasis occurs in tropical and subtropical regions, and not the United States (US). Such viewpoints are reflected in published distributions of leishmaniasis *(2)*. However, over time, the sand fly vector's distribution has expanded into previously non-endemic areas *(3)*, and leishmaniasis is well-documented in US animals *(4)*. In addition, multiple articles have described human acquisition of cutaneous leishmaniasis within Oklahoma and Texas, where leishmaniasis is now a reportable disease *(5)*. In fact, a cross-sectional observational study indicated that 41/69 cases (59%) of cutaneous leishmaniasis diagnosed from 2007-2017 in Texas were acquired locally rather than from travel *(6)*. Nevertheless, it is common for US providers to contemplate a leishmaniasis diagnosis in only patients with a history of foreign birth, travel, or military service, which in turn often excludes pediatric patients from consideration.

Within a 6-month period, 3 patients with cutaneous leishmaniasis presented to the Pediatric Infectious Diseases (ID) Clinic at the University of Texas Southwestern Medical Center (UTSW)/Children's Health Dallas. These cases reflect this disease's

changing epidemiology, since clinical isolates from these patients had genetic

polymorphisms that have been documented in Texan strains of *L. mexicana*.

Furthermore, we sequenced three *Leishmania* housekeeping genes and identified

significant differences between our clinical isolates, providing us with a novel

mechanism to type *L. mexicana* strains. Monitoring these sequences could permit

documentation of genetic variation among *Leishmania* isolates as this parasite expands

its geographic range in the US.

RESULTS

Patient presentations

3 cases of cutaneous leishmaniasis acquired in Texas were referred to the

Pediatric ID Clinic at UTSW/Children's Health Dallas over a six month period by their

treating dermatologists. Interestingly, none of these patients' family members had

lesions. Descriptions of these cases follow (**Figure 1**).

Case 1:

A 0-5 year old girl reported a non-healing nodular lesion on her right jawline that

had been present for months. She had not traveled outside north Texas. The lesion had

not responded to antibiotic therapy and worsened with steroids. A biopsy showed a

granulomatous infiltrate within the dermis, with amastigotes observed inside histiocytes,

diagnostic of cutaneous leishmaniasis. Genetic analysis performed at the Centers for

Disease Control and Prevention (CDC) demonstrated *L. mexicana* infection. She was

started on 6 mg/kg/day of fluconazole and, with 6 weeks of treatment, the lesion

essentially resolved.

Case 2:

A few months later, a 0-5 year-old boy who had no travel history developed a

non-healing nodular lesion on his left arm. It did not respond to antibiotics and ulcerated

after steroids were administered. He was seen in the ID clinic and had a nearly 2.5 cm-

diameter ulcer (**Fig 1A**). Biopsy demonstrated granulomatous inflammation with

innumerable amastigotes within histiocytes (**Fig 1B-D**). PCR amplification of parasite

DNA performed through the CDC detected *L. mexicana*. He received 6 mg/kg/day of

fluconazole and required 10 weeks of therapy for lesion resolution.

Case 3:

A 0-5 year old boy developed a nodular facial lesion that did not improve with

antibiotics and worsened with steroids. He had never traveled outside north

Texas/southern Oklahoma; however, he had been taken for daily walks at sunset at a

lake near his home. A biopsy and genetic sequencing performed at the CDC

demonstrated *L. mexicana* infection, leading to ID referral approximately 1 month after

patient 2. He was treated with fluconazole at 6 mg/kg/day, which was increased to 12

mg/kg/day after minimal clinical response. When his lesion failed to improve on

fluconazole, he was given topical paromomycin, compounded as in **Figure 1E** *(7)*. After

several months, his lesion resolved.

Genetic sequencing of patient isolates

Since there appeared to be an elevated incidence of local *Leishmania* infections,

we explored whether there was genetic variability in parasites from clinical samples.

With permission from patients 2 and 3, we obtained DNA from lesions for molecular

testing (termed Tx2 and Tx3, **Figure 2** and **Supplemental Material**). Unfortunately, a

sample from the initial patient (patient 1) was not available for further study. We then

proceeded with molecular testing as follows.

ITS2 sequencing:

The CDC sequences the ribosomal RNA-internal transcribed spacer 2 (ITS2)

region to identify the infecting *Leishmania* species, since having this information is

needed for appropriate therapeutic decisions *(7)*. Texas-specific ITS2 polymorphisms in

L. mexicana have been described, specifically A → C647 and T → C649 *(8)*. Our

sequence analysis confirmed that these ITS2 polymorphisms were seen in both of our

isolates (**Supplemental Figure and Table**).

Multilocus Sequence Analysis (MLSA):

We next explored whether there was intraspecies variation among isolates using

multilocus sequence analysis (MLSA). We selected a panel of 3 housekeeping genes:

mannose phosphate isomerase (MPI), malate dehydrogenase (MDH) and 6

phosphogluconate dehydrogenase (6PGD). We used gene-specific primers for

amplification and Sanger sequencing to identify synonymous/nonsynonymous SNPs in

coding regions. Of note, our primers did not amplify genetic material from uninfected

human samples.

We found that 6PGD was the most conserved gene, with the least number of

SNPs in both isolates. Interestingly, the MDH and MPI genes of Tx2 had significantly

diverged from reference strains. In fact, the MDH enzyme in Tx2 was prematurely

truncated (by 9 aa at the C terminus) due to transversion 922 (A→T) (**Figure 2,**

Supplemental Table). Tx3 also had several SNPs in the MDH and MPI genes that did

not match reference strains (**Figure 2, Supplemental Table**). Hence, MLSA analysis of

these three metabolic genes may provide a unique molecular epidemiological

mechanism to study genetic divergence in *L. mexicana*.

DISCUSSION

Here, we have documented 3 cases of cutaneous leishmaniasis due to *L. mexicana* acquired by pediatric patients within northern Texas. Since our described patients had normal immune systems and did not have infected family members, we believe they were individually exposed to sandflies outside their homes. Despite their relatively small number, our cases have significant bearing on US public health initiatives, as the likelihood of US patient exposure to what were formerly geographically-constrained tropical diseases will likely continue to increase as shifting vector distribution and other drivers continue *(3)*. In addition, we have provided a simple means to type strains of *L. mexicana* endemic to the United States. We propose that our methodology can be used to monitor genetic changes in *Leishmania* as the range of this parasite expands.

Our cases provide multiple therapeutic imputations for treating physicians in the US. Per Infectious Disease Society of America (IDSA) guidelines, treating single lesions from non-disseminating cutaneous species is optional, even in pediatric patients *(7)*. However, we treated our patients for cosmetic reasons, since each had facial or large lesions. The referring dermatologists were hesitant to utilize local cryotherapy or brachytherapy (standard for single *L. mexicana*-induced lesions) due to patient age. IDSA guidelines indicate that employing fluconazole is reasonable for US pediatric cutaneous leishmaniasis patients *(7)*. Therefore, our patients were initially treated with oral fluconazole, which has a ~50% success rate among all species *(9, 10)*; 2 of our patients responded. Fluconazole is generally well-tolerated, has good oral bioavailability, and achieves epidermis/dermis concentrations above plasma levels *(11,*

12). A dose of 6 mg/kg typically is recommended for pediatric cutaneous leishmaniasis *(7)*. However, for serious fungal infections, many authors propose higher doses (12 mg/kg) in children based on fluconazole's lower half-life, higher volume of distribution, more rapid clearance, and minimal side effect profile in pediatric patients, to prevent treatment failure or relapse *(13)*, *(14)*. Combining this literature with our experience, initiating higher doses (10-12 mg/kg/day *(15)*) in younger ($\leq$ 5-year-old) pediatric leishmaniasis patients may be worthwhile to maximize likelihood and rapidity of response. Furthermore, we note our third patient did not respond to months of fluconazole therapy. Consistent with IDSA guidelines, we propose that pediatric leishmaniasis patients be transitioned to alternate agents if they do not begin to respond to high-dose fluconazole in 4-6 weeks *(7)*. Notably, the topical paromomycin employed in patient 3 can be difficult to acquire in the US, as it requires compounding by a willing pharmacy and investigational drug applications, so we did not use it initially in our patients.

We also determined that our patients' *Leishmania* isolates have undergone significant genetic changes that may offer insights into evolutionary biology. Notably, it is now more common for patients in Texas to acquire leishmaniasis locally than from travel *(5, 6)*. The CDC has described a specific polymorphism in the ITS2 sequence of *L. mexicana* in Texas-endemic strains; we replicated these results in our patients' isolates. Furthermore, we provide a mechanism for strain-typing isolates of this newly-endemic parasite using 3 metabolic genes. Our results demonstrate the power of MLSA analysis as a simple yet important molecular epidemiological tool to study *Leishmania*

genetic divergence within the US. Since clusters of leishmaniasis cases have been

described, our technique could potentially be used to characterize outbreaks. The large

number of genetic changes that we found using a limited number of isolates suggests

that Texas-specific strains of *L. mexicana* may be under significant evolutionary

selection pressure, which in turn may lead to novel mutations. We plan to continue to

monitor available isolates for this possibility over time.

Although cases of leishmaniasis certainly have been described in the United

States, our case discussions have typically been met with surprise from clinicians and

scientists alike. One factor that may lead to this underappreciation of endemicity is that

leishmaniasis is a reportable disease in Texas, but not in other states *(6)*. We would

argue that leishmaniasis should be a reportable disease nationwide so that its incidence

and distribution can be monitored by public health officials. Furthermore, we propose

that such information could be collected in conjunction with our strain-typing techniques

to characterize ongoing genetic variation in this parasite as its endemic area expands.

Hence, the cases of cutaneous leishmaniasis described here have significant

microbiological, treatment and public health implications.

METHODS

Molecular analysis/Strain typing*:*

For patient 2 in this report, a clinical sample (termed Tx2) was obtained and briefly

cultured at UTSW as promastigotes in Schneider's Insect cell media (Sigma, S9895)

supplemented with 20% FBS (GeminiBio, 100-106) and 1% penicillin-streptomycin

(Sigma, P4333). Time in culture was limited to minimize genetic changes *in vitro*. DNA

was extracted using the DNAeasy Blood and tissue Kit (Qiagen, 69504) according to

manufacturer's instructions. For patient 3 (Tx3), we received extracted DNA from the

CDC (Thanks to Yvonne Qvarnstrom*,* CDC)*,* which had been generated in a similar

manner to Tx2. Extracted DNA was used to amplify the rRNA-internal transcribed

spacer (ITS2) region for species identification (**Supplemental Figure**) and three

housekeeping genes: mannose phosphate isomerase (MPI), malate dehydrogenase

(MDH) and 6 phosphogluconate dehydrogenase (6PGD) with gene specific primers for

L. mexicana. Sequences for all primers are in the **Supplemental Table**. The CDS

region for these genes was then used for MLSA to explore genetic variation among

isolates. Briefly, each gene was amplified with high fidelity DNA polymerase Primestar

Max (Takara Bio, RO45A) using forward and reverse primers binding in upstream and

downstream coding regions, respectively. PCR amplified fragments were Sanger

sequenced in the UTSW McDermott Center Sequencing Core facility using Life

Technologies® Dye Terminator 3.1 chemistry and 3730XL Genetic Analyzers.

Single nucleotide polymorphism (SNP) analysis*:*

254   Each gene was sequenced bidirectionally using 2 sets of forward (ExtF, IntF) and

255   reverse (ExtR and IntR) primers. ExtF and ExtR bind outside of the coding region and

256   IntF and IntR bind in the coding region. Due to the sequence variability found in the Tx2

257   MPI gene, multiple internal primers were used. SNP analysis was performed using the

258   sequence alignment tools EMBOSS needle and Clustal Omega (www.ebi.ac.uk).

REFERENCES

1.   Wetzel DM, Phillips MA. Chapter 67: Chemotherapy of protozoal infections:
amebiasis, giardiasis, trichomoniasis, trypanosomiasis, leishmaniasis, and other
protozoal infections. In: Brunton L, editor. Goodman and Gilman's The Pharmacological
Basis of Therapeutics. 13 ed. New York, NY: McGraw-Hill Medical; 2023. p. 1309-24.

2.   https://www.cdc.gov/dpdx/leishmaniasis/index.html.

3.   Gonzalez C, Wang O, Strutz SE, Gonzalez-Salazar C, Sanchez-Cordero V,
Sarkar S. Climate change and risk of leishmaniasis in North America: predictions from
ecological niche models of vector and reservoir species. PLoS Negl Trop Dis. 2010 Jan
19;4(1):e585.

4.   Petersen CA. Leishmaniasis, an emerging disease found in companion animals
in the United States. Top Companion Anim Med. 2009 Nov;24(4):182-8.

5.   Wright NA, Davis LE, Aftergut KS, Parrish CA, Cockerell CJ. Cutaneous
leishmaniasis in Texas: A northern spread of endemic areas. J Am Acad Dermatol.
2008 Apr;58(4):650-2.

6.   McIlwee BE, Weis SE, Hosler GA. Incidence of endemic human cutaneous
leishmaniasis in the United States. JAMA Dermatol. 2018 Sep 1;154(9):1032-9.

7.   Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al.
Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious
Diseases Society of America (IDSA) and the American Society of Tropical Medicine and
Hygiene (ASTMH). Am J Trop Med Hyg. 2016 Dec 07.

8.   de Almeida ME, Steurer FJ, Koru O, Herwaldt BL, Pieniazek NJ, da Silva AJ.
Identification of Leishmania spp. by molecular amplification and DNA sequencing

analysis of a fragment of rRNA internal transcribed spacer 2. J Clin Microbiol. 2011

Sep;49(9):3143-9.

9.   Prates FV, Dourado ME, Silva SC, Schriefer A, Guimaraes LH, Brito MD, et al.

Fluconazole in the treatment of cutaneous leishmaniasis caused by *Leishmania*

braziliensis: a randomized controlled trial. Clin Infect Dis. 2017 Jan 1;64(1):67-71.

10.   Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH.

Fluconazole for the treatment of cutaneous leishmaniasis caused by *Leishmania major*.

N Engl J Med. 2002 Mar 21;346(12):891-5.

11.   Faergemann J. Pharmacokinetics of fluconazole in skin and nails. J Am Acad

Dermatol. 1999 Jun;40(6 Pt 2):S14-20.

12.   Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum,

epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol.

1993 Mar;18(2):102-6.

13.   Pacifici GM. Clinical pharmacology of fluconazole in infants and children. Clin

Med Investig. 2020;5:10.15761.

14.   Watt K, Benjamin DK, Jr., Cohen-Wolkowiez M. Pharmacokinetics of antifungal

agents in children. Early Hum Dev. 2011 Mar;87 Suppl 1(Suppl 1):S61-5.

15.   Wade KC, Benjamin DK, Jr., Kaufman DA, Ward RM, Smith PB, Jayaraman B, et

al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young

infants. Pediatr Infect Dis J. 2009 Aug;28(8):717-23.

ACKNOWLEDGEMENTS

We are grateful to staff members in the UTSW/Children's Health Dallas Pediatric

Infectious Diseases clinic for their flexibility in patient scheduling to ensure that these

leishmaniasis patients saw Dr. Wetzel. We thank the Texas Department of Health for

discussing these cases with us when we reported them, members of the UT

Southwestern and global parasitology communities for their support and interest in this

experience, and the Pediatric ID Division at UT Southwestern for providing helpful

advice. We also thank Dr. Yvonne Qvarnstrom at the CDC for assisting us with

acquiring leishmanial DNA from patient 3. Dr. Nepal is funded by American Heart

Association Postdoctoral Fellowship 916875. Dr. Wetzel was supported by a Children's

Clinical Research Advisory Committee (CCRAC) Early Investigator Award, a 2019

Harrington Scholar-Innovator Award, NIH R01 AI146349, a Welch Grant for Chemistry

(I-2086) and funds from the UTSW Department of Pediatrics. The funders did not play a

role in the writing of this manuscript. Reporting of this small case series ($\leq$ 3 patients)

was exempt from UTSW/Children's Health Dallas-IRB approval. However, the patients

in this study provided permission for images to be used and for clinical samples to be

taken; these activities were approved by the IRBs at both UTSW and Children's Health

(STU-2019-0754).

FIGURES

Figure 1

E Clinical features	Case 1	Case 2	Case 3
Gender	Female	Male	Male
Race/ethnicity	Hispanic	Hispanic	Caucasian
Travel history	None	None	None
Lesion location	R inferior jaw	L arm	R temple
Lesion size/diameter	1.5 X 1.5 cm	2.5 X 2.5 cm	1 X 2 cm
Duration of symptoms before diagnosis	6 months	5 months	4 months
Infective species	*L. mexicana*	*L. mexicana*	*L. mexicana*
Initial lab abnormalities*	None performed	Eosinophilia (AEC 740) Elevated IgE (215)	Mild neutropenia (ANC 1300) Eosinophilia (AEC 1300) Mildly low IgG (241)
Treatment	Fluconazole (6 mg/kg) X 6 wks	Fluconazole (6 mg/kg) X 10 wks	Fluconazole (6 mg/kg X 5 wks; 8 mg/kg X 3 weeks; 12 mg/kg X 6 wks) →· Topical paromomycin (15% paromomycin, 12% MBCL in paraffin) X 10 days on, 10 days off X 3 iterations

Figure 1: Clinical features of patients presented. A-D) Clinical and histopathological

evaluation of patient 2. **A)** Approximately 2.5 cm lesion on the left arm clinically

consistent with cutaneous leishmaniasis. Scale bar = 1 cm. **B)** Granulomatous

inflammation with numerous histiocytes (100x magnification, H&E). Sample shared from

Sagis Diagnostics, Houston, TX. **C)** Small, round amastigotes are visible within

histiocytes in the reticular dermis (500x magnification, H&E). **D)** Amastigotes within

histiocytes with visible kinetoplasts at arrowheads (1000x magnification, oil immersion,

H&E). **E)** Patient demographics, signs and symptoms, and laboratory findings. *Normal

studies in Case 2 included CBC, remainder of differential, C-reactive protein, and

chemistries including liver function panel. Normal studies in Case 3 included CBC,

remainder of differential, C-reactive protein, chemistries including liver function panel,

IgA, IgM, and IgE. All laboratory abnormalities resolved after treatment. ANC, Absolute

neutrophil count. AEC, Absolute eosinophil count.

Figure 2

A

Substitution	MPI		MDH		PGD	
	Tx2	Tx3	Tx2	Tx3	Tx2	Tx3
Transitions	252 (G→A) 417 (C→T) 501 (A→G) 504 (C→T) **529 (A→G)** **592 (A→G)** 612 (T→C) **661 (T→C)** 693 (A→G) 711 (T→C) 720 (G→A) **1148 (A→G)** 1182 (G→A)	592 (A→G) 612 (T→C) 661 (T→C)	**185 (T→C)** **223 (A→G)** **226 (C→T)** 300 (T→C) 332 (T→C) **515 (A→G)** **523 (A→G)** 846 (C→T) **868 (A→G)** **869 (T→C)**	523 (A→G)	990 (A→G)	990 (A→G)
Transversion	483 (A→T) 493 (A→T) **545 (C→G)** **605 (C→A)** **663 (C→G)** 870 (C→A) 1032 (C→G)		**184 (T→A)** 292 (A→C) 378 (T→G) 922 (A→T) 946 (T→A)	292 (A→C)	729 (G→T)	

B

Figure 2. **Genetic analysis of clinical isolates. A**) SNPs reported after MLSA

analysis. The nonsynonymous SNPs are in bold. **B)** Venn diagram showing SNPs

reported on genes analyzed by MLSA.

SUPPLEMENTAL MATERIAL

Supplemental Methods, Results and Discussion:

Additional specific details regarding genetic sequencing of the clinical isolates from

these patients are described below. Of interest, this analysis can be done after sampling

lesions with a flocked nylon swab, which provides a less invasive means of diagnosis in

children. All sequences described in this manuscript have been submitted to TriTryp DB

(TriTrypDB).

ITS2: We performed sequence analysis on the rRNA-internal transcribed spacer 2

(ITS2) region, which shows a previously reported Texas-specific polymorphism, C647

and C649, on both Tx2 and Tx3. For this analysis, FJ948434 was used as a reference

strain. However, alignments of the FJ948434 ITS2 sequence with 25 publicly available

non-US *L. mexicana* ITS2 sequences were identical. Isolates' ITS2 sequences are

shown in the **Supplemental Figure**, and primer sequences are contained in the

Supplemental Table.

Metabolic enzymes: For the three metabolic enzymes sequenced, *Leishmania*

mexicana MHOM/GT/2001/U1103 (Guatemala) was used as a reference strain, since it

is the *L. mexicana* strain with the most widely available genomic sequence *(1)*.

MDH: SNP analysis in the CDS of the MDH gene showed a total of 15 SNPs in Tx2. We

identified nine base transitions: 185 (T→C), 223 (A→G), 226 (C→T), 300 (T→C), 332

(T→C), 515 (A→G), 523 (A→G), 846 (C→T), 868 (A→G), 869 (T→C), and five base

transversions, 184 (T→A), 292 (A→C), 378 (T→G), 922 (A→T), 946 (T→A). Tx3 had

two SNPs, a base transition at 523 (A→G) and a transversion at 292 (A→C). We note

that SNPs 184 (T→A), 185 (T→C), 223 (A→G), 226 (C→T), 515 (A→G), 523 (A→G),

868 (A→G), 869 (T→C) were nonsynonymous and resulted in amino acid changes

(**Figure 2, Supplemental Table**). Of particular interest, MDH in Tx2 was prematurely

truncated (by 9 aa at the C terminus) due to transversion 922 (A→T). However, this

truncation would not be expected to affect its enzymatic function *(2)*.

PGD: Similarly, we identified 2 SNPs on coding region of PGD gene of Tx2,

transversion at 729 (G→T) and single transition 990 (A→G). Tx3 had a single base

transition at 990 (A→G).

MPI: The MPI gene for the Tx3 isolate had 3 base transitions, 592 (A→G), 612 (T→C),

661 (T→C). On the other hand, for Tx2, the MPI gene had 20 SNPs: transitions 252

(G→A), 417 (C→T), 501 (A→G), 504 (C→T), 529 (A→G), 592 (A→G), 612 (T→C), 661

(T→C), 693 (A→G), 711 (T→C), 720 (G→A), 1148 (A→G), 1182 (G→A) and

transversions: 483 (A→T), 493 (A→T), 545 (C→G), 605 (C→A), 663 (C→ G), 870

(C→A), 1032 (C→G). SNPs 529 (A→G), 545 (C→G), 592 (A→G), 605 (C→A), 661

(T→C), 663 (C→G), 1148 (A→G) were nonsynonymous.

Supplemental Figure

```
399   FJ948434.1     ATACACACATGTGCACTCTCCTTTGTGTGGGTGCGCGCGTGGAAAAACTCCTCTCTGGTG     660
400   Tx2.ITS2       ATACACACATGTGCACTCTCCTTTGTGTGGGTGCGCGCGTGGAAAACCCCCTCTCTGGTG     224
401   Tx3.IT2        ATACACACATGTGCACTCTCCTTTGTGTGGGTGCGCGVGTGGAAAACCCCCTCTCTGGTG     224
402                  ********************************************** * **********
```

404   **Supplemental Figure.** Sequences of the relevant ITS2 region in a representative non-

405   US reference strain (FJ948434.1), compared to Tx2 and Tx3.

406
407

408 **Supplemental Table**

Gene	Accession number	Amplicon size (bp)	CDS length (bp)	Location	Primer sequence
ITS2		Variable	N/A	18S ribosome	ITS2.F: GCATGCCATATTCTCAGTGTC ITS2.R: GGCCAACGCGAAGTTGAATTC ITS2.R1: GAATTCTCGTTTTGGTTTTTTG
Glucose-6-phosphate dehydrogenase (*g6pdh)*	XM_003879281.1	1700	1440	Chr 34	ExtF: TTACTGGCGCTTAGTCCCATCATA ExtR: TAAGAGCGGAATCGGGTGC IntF: GCAGGCAACTATCTGTCAGAGAA IntR: ATGTTGAGCGAGGGCGCTG
Malate dehydrogenase (*mdh*)	XM_003878549.1	1166	951	Chr 33	ExtF: TGCCGTACAATCCATCTCGC ExtR: AACGACGCCGCATCATTGTG IntF: ATCATCAGCAACCCTGTCAACAGC IntR: TAACGTCGTACGGGCTTGC
Mannose phosphate isomerase (*mpi*)	XM_003879281	1471	1266	Chr 31	ExtF: TCTGGGTTGTGTAGTAGCGTC ExtR: AATTCGCCTGCCACTGTG IntF: TCCAGAGCTGGCTGAGCTTGTAG IntR: CATACACGGTCGTCATCATAGTC SeqF1: CTTTGAGGCACTCTGCTGC SeqF2: GACTATGATGACGACCGTGTATG SeqR: GTCGTATCGTTCACCTTGGCAG SeqR1: CGTCAATGTTGAAGGAAACTCGGT

411 **Supplemental Table. Genes and primer sequences used for MLSA analysis.**

SUPPLEMENTAL REFERENCES

1. Rogers MB, Hilley JD, Dickens NJ, Wilkes J, Bates PA, Depledge DP, et al. Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res. 2011 Dec;21(12):2129-42.

2. Leroux A, Fleming-Canepa X, Aranda A, Maugeri D, Cazzulo JJ, Sánchez MA, and Nowicki C. Functional characterization and subcellular localization of the three malate dehydrogenase isozymes in Leishmania spp. Mol Biochem Parasitol. 2006: 149(1):74-85.